HERANTIS PHARMA OYJ Herantis Pharma Plc announced the dosing of the first healthy volunteer in the Phase 1a clinical study for HER-096. The ase 1a clinical study will assess safety, tolelerability, and blood -brain barrier penetration of subcutaneously administered HER-096. The study takes place in Turku, Finland conducted by the contract research organization, CRST.
HER-096 is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
